163 related articles for article (PubMed ID: 23407367)
1. Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma.
Lansoy-Kuhn C; Picquenot JM; Edet-Sanson A; Mechken F; Laberge-Le Couteulx S; Cornic M; Vera P
Nucl Med Commun; 2013 Apr; 34(4):340-6. PubMed ID: 23407367
[TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
3. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
5. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
7. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
8. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
10. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
11. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
12. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
13. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
17. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
[TBL] [Abstract][Full Text] [Related]
18. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
[TBL] [Abstract][Full Text] [Related]
19. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
20. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
